Affiliation:
1. Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Heilongjiang Province China
2. Clinical Research Center for Colorectal Cancer in Heilongjiang Harbin Medical University Cancer Hospital Harbin Heilongjiang Province China
Abstract
AbstractColorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death worldwide. Clinical research results have provided more treatment opportunities for CRC patients, showing that an optimal combination of existing drugs and new drugs is needed to mitigate the burden of this disease. In this review, we have summarized recent advances in drug clinical research for CRC in 2022, including chemotherapy, targeted therapy, and immunotherapy, to find opportunities for substantial improvements in drug discovery and clinical development methods.
Funder
National Natural Science Foundation of China
Subject
Pharmacology (medical),Cancer Research,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Drug Discovery,Oncology
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献